Industry Overview

Liquid biopsy market was valued at $3.0 billion in 2025 and is projected to reach $12.1 billion by 2035, growing at a CAGR of 15% during the forecast Period (2026-2035). The Market growth is driven by the rising cancer burden, demand for non-invasive diagnostics, personalized medicine, and expanding applications beyond oncology (prenatal, infectious diseases). its key factors fueling this expansion include technological advancements, increased R&D funding, and the shift to real-time monitoring, although challenges like high costs, reimbursement issues, and variable sensitivity for early detection persist. North America currently leads the market, with Asia-Pacific emerging as a key growth region.

Market Dynamics

Shift Toward Eco-Friendly and Low-VOC Solutions

One of the strongest drivers of growth in the global polymer dispersion market is the increasing shift toward environmentally friendly and low-VOC (volatile organic compound) formulations. Governments worldwide are imposing stricter regulations to limit VOC emissions and reduce environmental pollution, particularly in coatings, adhesives, and construction materials. This regulatory pressure has encouraged manufacturers and end-users to replace traditional solvent-based systems with water-based polymer dispersions that offer lower emissions, improved safety profiles, and better compliance with environmental standards. As both industries and consumers prioritize sustainability, demand for eco-friendly polymer dispersions continues to rise across multiple end-use sectors.

Expanding Demand Across End-Use Industries

Another significant driver for the polymer dispersion market is the expansion of key end-use industries, including paints and coatings, adhesives and sealants, textiles, construction, automotive, and packaging. Polymer dispersions serve as essential binders and performance enhancers in these applications, delivering enhanced adhesion, durability, flexibility, weather resistance, and aesthetic properties. Rapid industrialization, urbanization, and infrastructure growth especially in emerging economies such as China, India, and Southeast Asia are fueling increased consumption of polymer dispersions in architectural coatings, high-performance adhesives, and specialty textile finishes. As these industries continue to grow, they are expected to sustain and expand demand for polymer dispersion products.

Technological Advancements and Product Innovation

Technological innovation is also a key market driver, as continuous research and development in polymer chemistry and formulation science leads to advanced dispersion products with superior performance characteristics. Manufacturers are developing tailored solutions that offer improved stability, enhanced mechanical properties, better chemical resistance, and application-specific performance benefits. Innovations include waterborne, bio-based, and hybrid polymer dispersions designed to meet both sustainability goals and evolving industrial requirements. These advancements not only broaden the range of applications for polymer dispersions but also help manufacturers differentiate their offerings in a competitive market, ultimately driving greater adoption across sectors such as automotive, electronics, and specialty coatings.

Market Segmentation

• Based on the type, the market is segmented into circulating tumor cells, circulating tumor dna, and others.
• Based on the cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, colorectal cancer, and other cancers.
• Based on the end-user, the market is segmented into hospitals and laboratories, and academic and research centres.

Circulating Tumor DNA (ctDNA) Segment to Grow at a Considerable Market Share

Circulating Tumor DNA (ctDNA) emerges as the single largest and leading segment. This dominance is driven by its high clinical relevance, broad applicability across multiple cancer types, and strong adoption in both hospitals and advanced laboratories. ctDNA-based assays enable minimally invasive, highly sensitive detection of genetic mutations, disease progression, and treatment response through simple blood samples, making them more practical and scalable than circulating tumor cells or other emerging biomarkers such as extracellular vesicles. The rapid integration of next-generation sequencing (NGS), growing use of liquid biopsy in early cancer screening and therapy monitoring, and increasing preference for non-invasive diagnostic techniques collectively reinforce ctDNA as the most commercially significant and revenue-generating segment, positioning it as the primary driver of overall market growth.

Lung Cancer: A Key Segment in Market Growth

Lung cancer emerges as the single most important key segment driving overall market growth among the listed categories, primarily due to its high global disease burden, need for early diagnosis, and increasing adoption of advanced diagnostic technologies. Lung cancer remains one of the leading causes of cancer-related mortality globally, with a large proportion of cases diagnosed at advanced stages, creating a strong clinical demand for accurate, rapid, and minimally invasive diagnostic and monitoring solutions. The segment benefits significantly from the growing use of precision oncology, where repeated molecular profiling is required to guide targeted therapies and monitor treatment response. Technological advancements have enabled better detection of actionable biomarkers associated with lung cancer, supporting earlier intervention and personalized treatment planning.

Additionally, the rise in screening initiatives for high-risk populations, such as smokers and the elderly, has increased test volumes linked to lung cancer diagnostics. Pharmaceutical and biotechnology companies are also heavily focused on lung cancer drug development, further accelerating companion diagnostics and routine testing adoption. Compared to other cancer types, lung cancer generates higher recurring demand due to disease aggressiveness, frequent monitoring needs, and therapy resistance assessment, making it the most influential segment contributing to sustained market expansion across both clinical and research settings.

Regional Outlook

The global liquid biopsy market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

Asia-Pacific Region to Hold a Substantial Growth Rate

In the Asia-Pacific region, China dominates the global polymer dispersion market due to its extensive manufacturing base, rapid urbanization, and strong demand from key end-use industries such as construction, paints and coatings, adhesives, textiles, and paper. The country is the world’s largest producer and consumer of architectural and industrial coatings, where polymer dispersions are widely used for water-based formulations. Large-scale infrastructure development, residential construction, and renovation activities continue to drive sustained demand for decorative and protective coatings, directly supporting polymer dispersion consumption. China also benefits from a well-established chemical manufacturing ecosystem, with abundant availability of raw materials, cost-efficient production, and a dense network of domestic and multinational polymer producers.

Additionally, increasing environmental regulations promoting low-VOC and water-borne products have accelerated the shift from solvent-based systems to polymer dispersions, further strengthening market growth. The presence of major global players alongside strong local manufacturers enables continuous capacity expansion and technological advancements, particularly in acrylic and vinyl dispersions. China’s dominance is reinforced by high export volumes of coatings, adhesives, textiles, and finished consumer goods, all of which rely heavily on polymer dispersions. Combined with supportive government policies for sustainable manufacturing and ongoing investments in industrial modernization, China remains the leading country shaping volume consumption, pricing dynamics, and overall growth trends in the global polymer dispersion market.

Market Players Outlook

The major companies operating in the global liquid biopsy market include F. Hoffmann-La Roche Ltd. , Guardant Health, Illumina, Inc., Myriad Genetics, Inc., Natera, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In January 2026, BillionToOne announced that its Northstar Select liquid biopsy test has been selected for the LC-SCRUM-TRY clinical study at the National Cancer Center Hospital East in Japan. This nationwide, multi-center study aims to investigate drug resistance mechanisms in lung cancer. Launched in 2020, it involves over 100 institutions and has analyzed around 2,000 specimens from patients with advanced non-small cell lung cancer (NSCLC). Given the difficulties in obtaining tissue biopsies from drug-resistant tumors, this study will utilize plasma-based liquid biopsy using cell-free DNA (cfDNA) for non-invasive genomic analysis.
• In July 2025, NeoGenomics launched the NEO PanTracer LBx, a noninvasive blood-based comprehensive genomic profiling (CGP) test, enhancing its PanTracer portfolio. This test utilizes circulating tumor DNA (ctDNA) obtained from a simple blood draw, facilitating access to vital biomarker information when tissue samples are lacking. It promises a rapid seven-day turnaround, analyzing over 500 genes, including MSI and bTMB, for timely insights. The PanTracer LBx can be ordered standalone, as a reflex to failed tissue testing, or alongside tissue analysis, with applications in therapy selection, trial matching, and longitudinal monitoring.
• In June 2025, Liquid biopsy, offered at Florida Cancer Specialists & Research Institute, is a minimally invasive blood test that enhances cancer diagnosis and treatment personalization by detecting circulating tumor DNA (ctDNA). This efficient method allows for easy repeatability compared to traditional biopsies. It integrates genomic insights to improve outcomes for patients with various cancers, particularly advanced stages of lung, colorectal, breast, and prostate cancers. Utilizing advanced sequencing technology, FCS provides rapid, high-quality molecular testing, helping physicians assess and tailor treatments effectively. Jennifer Gass, PhD, emphasizes its role in delivering quick genetic information for better treatment targeting and patient monitoring.
• In October 2024, QIAGEN expanded its automated liquid biopsy portfolio, enhancing technologies for oncology, prenatal care, and organ transplant applications. Liquid biopsy employs biofluid samples to detect disease biomarkers non-invasively, supporting personalized medicine in real-time tumor monitoring. Key updates include the EZ1&2 ccfDNA Kit, which now automates simultaneous processing of 24 samples with up to 10 mL of serum or plasma, and introduces a urine protocol for higher yields of circulating cell-free DNA (ccfDNA). Additionally, the new QIAsymphony DSP Circulating DNA Kits (96 and 192) optimize ccfDNA extraction from larger sample volumes, catering to laboratories of varying sizes. These kits comply with IVD regulations, ensuring their role in high-sensitivity analyses integral to non-invasive diagnostic procedures for early and accurate cancer detection.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global liquid biopsy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.